Brain exposure for antibodies
The blood-brain barrier is a continuous endothelium with tight junctions and active efflux, and it is very good at keeping large molecules out. For a systemically dosed antibody, the fraction that reaches brain tissue is small, commonly cited as well under one percent of the plasma level at steady state. Any central nervous system antibody program has to have an answer for that number.
Why it matters more than it looks
A hundredfold to thousandfold drop in exposure means the dose that produces a useful brain concentration may be impractical, and it means target engagement in the periphery can dominate the pharmacology. It also complicates interpretation: a negative clinical result can mean the target was wrong, or it can mean the drug never got there in useful quantity, and only an exposure and engagement measurement separates the two.
Approaches to getting more in
Receptor-mediated transcytosis. Fusing or engineering a binding module against a receptor expressed on brain endothelium, most commonly the transferrin receptor, recruits the antibody into transcytosis. Affinity matters in an unintuitive way: binding too tightly can trap the molecule at the endothelium rather than releasing it on the other side, so moderate affinity or pH-dependent release often works better than maximum affinity. Bispecific formats that pair a therapeutic arm with a transport arm are the usual implementation.
Direct delivery. Intrathecal or intracerebroventricular dosing sidesteps the barrier and brings its own distribution and practicality problems.
Focused ultrasound with microbubbles transiently opens the barrier and has moved into clinical study.
Smaller formats. Single domain binders cross no better per molecule in most reports, but their size, tissue penetration and short half-life change the exposure profile, and they are attractive as the payload arm of a transport construct.
Measuring exposure
- Correct for residual blood. Brain tissue contains blood, and without perfusion or a vascular marker correction, the measured brain concentration is mostly plasma.
- Separate parenchyma from vasculature. A molecule bound to the endothelium is not in the brain, and a transport arm can produce exactly that picture.
- Measure engagement, not only concentration. A target occupancy readout, a downstream biomarker, or displacement of a tracer tells you the molecule reached the target. Concentration in a homogenate does not.
- Use cerebrospinal fluid carefully. It is accessible and it is an imperfect proxy for parenchymal exposure.
What this means for design
Decide early whether the program needs brain exposure at all, because some proposed mechanisms act on peripheral pools. If it does, plan the transport approach at the design stage rather than bolting it on later, since adding a transport arm changes format, valency, manufacturing and the entire pharmacokinetic profile, and every binding and functional number has to be re-measured on the final construct.
How we work on it
We build the binder and the assays; exposure work happens with partners who run the animal studies. What we can do at the bench is make sure the construct you take into those studies is the construct you tested, characterized in the final format.